Impacts of an opioid overdose prevention intervention delivered subsequent to acute care

Injury Prevention

Volumn 25, Issue 3, 2019, Pages 191-198

  Banta Green, Caleb J ^a   Coffin, Phillip O ^b,c   Merrill, Joseph O ^a   Sears, Jeanne M ^a,d   Dunn, Chris ^e   Floyd, Anthony S ^a   Whiteside, Lauren K ^e   Yanez, Norbert D ^f   Donovan, Dennis M ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTE FOR WORK AND HEALTH   (Canada)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

behavior change; drugs; health education

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; DRUG OVERDOSE; EARLY INTERVENTION; FEMALE; HEALTH SURVEY; HOSPITAL EMERGENCY SERVICE; HUMAN; MALE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; OPIATE ADDICTION; PROGRAM EVALUATION; PSYCHOLOGY;

ADULT; ANALGESICS, OPIOID; DRUG OVERDOSE; EARLY MEDICAL INTERVENTION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PROGRAM EVALUATION;

EID: 85049751953     PISSN: 13538047     EISSN: 14755785     Source Type: Journal    
DOI: 10.1136/injuryprev-2017-042676     Document Type: Article

References (40)

1. Jones CM, Mack KA, Paulozzi LJ, et al. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013;309:657-9.
2. Rudd RA, Seth P, David F, et al. Increases in drug and opioid-involved overdose deaths-United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016;65:1445-52.
3. Weiss AJ, Elixhauser A, Barrett ML, et al. Opioid-related inpatient stays and emergency department visits by state, 2009-2014. HCUP Stat Br 2014;219:1-15.
4. McGregor C, Darke S, Ali R, et al. Experience of non-fatal overdose among heroin users in Adelaide, Australia: Circumstances and risk perceptions. Addiction 1998;93:701-11.
5. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 2005;100:1823-31.
6. Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172-9.
7. Davidson PJ, Ochoa KC, Hahn JA, et al. Witnessing heroin-related overdoses: The experiences of young injectors in San Francisco. Addiction 2002;97:1511-6.
8. Strang J, Powis B, Best D, et al. Preventing opiate overdose fatalities with takehome naloxone: Pre-launch study of possible impact and acceptability. Addiction 1999;94:199-204.
9. Miller WR, William R, Rollnick S. Motivational interviewing : Preparing people for change: Guilford Press, 2002.
10. Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2004;140:557.
11. Estee S, Wickizer T, He L, et al. Evaluation of the Washington state screening, brief intervention, referral to treatment project. Med Care 2010;48:18-24.
12. Gentilello LM, Rivara FP, Donovan DM, et al. Alcohol interventions in a trauma center as a means of reducing the risk of injury recurrence. Ann Surg 1999;230:473-80. discussion 480-3.
13. Bohnert AS, Bonar EE, Cunningham R, et al. A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depend 2016;163:40-7.
14. Blow FC, Walton MA, Bohnert ASB, et al. A randomized controlled trial of brief interventions to reduce drug use among adults in a low-income urban emergency department: The HealthiER You study. Addiction 2017;112:1395-405.
15. Fisher JD, Fisher WA, Amico KR, et al. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Heal Psychology 2006;25:462-73.
16. Maxwell S, Bigg D, Stanczykiewicz K, et al. Prescribing naloxone to actively injecting heroin users. J Addict Dis 2006;25:89-96.
17. Sporer KA, Kral AH. Prescription naloxone: A novel approach to heroin overdose prevention. Ann Emerg Med 2007;49:172-7.
18. Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014. MMWR Morb Mortal Wkly Rep 2015;64:631-5.
19. WHO. Community management of opioid overdose: Springer Reference, 2014.
20. SAMHSA. Opioid Overdose TOOLKIT facts for community members five essential steps for first reponders information for prescribers safety advice for patients & family members recovering from opioid overdose. : HHS Publ, 2013:4742: 13. http://www. store. samhsa. gov
21. Doe-Simkins M, Walley AY, Epstein A, et al. Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009;99:788-91.
22. Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: An evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008;103:979-89.
23. Lagu T, Anderson BJ, Stein M. Overdoses among friends: Drug users are willing to administer naloxone to others. J Subst Abuse Treat 2006;30:129-33.
24. Seal KH, Downing M, Kral AH, et al. Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: A survey of streetrecruited injectors in the San Francisco Bay Area. J Urban Health 2003;80:291-301.
25. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ 2013;346:f174.
26. Strang J, Bird SM, Parmar MK. Take-home emergency naloxone to prevent heroin overdose deaths after prison release: Rationale and practicalities for the N-ALIVE randomized trial. J Urban Health 2013;90:983-96.
27. Moyers TB, Martin T, Manuel JK, et al. Revised global scales: Motivational Interviewing Treatment Integrity 3.1.1 (MITI 3.1.1). 2010 https://casaa. unm. edu/download/miti3-1. pdf (accessed 25 Oct 2017).
28. Pintilie M. Competing risks : A practical perspective. West Sussex, England: John Wiley & Sons, 2006. https://books. google. com/books hl= en& lr=& id= ZRh2gl-U6isC& oi= fnd& pg= PR7& dq= Pintilie+ M.+ Competing+ Risks:+ A+ Practical+ Perspective.+ West+ Sussex, + England:+ Wiley% 3B+ 2006.& ots= NdLT548oNj& sig= Jm47omSXqSKRT8K0-Ejb0KEbq-0# v= onepage& q& f= false (accessed 25 Oct 2017).
29. Cleves MA, Gould WW, Gutierrez RG, et al. An introduction to survival analysis using Stata, 2008.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
31. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med 2013;158:1-9.
32. Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: A national cohort study in England. Addiction 2016;111:298-308.
33. Larimer ME, Malone DK, Garner MD, et al. Health care and public service use and costs before and after provision of housing for chronically homeless persons with severe alcohol problems. JAMA 2009;301:1349-57.
34. Banta-Green CJ, Coffin PO. Commentary on Pierce et al. (2016): Raising the bar of addiction treatment-first do no harm. Addiction 2016;111:309-10.
35. Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphinenaloxone treatment for opioid-dependent youth: Data from a randomized trial. Addiction 2010;105:1616-24.
36. Hser YI, Evans E, Huang D, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 2016;111:695-705.
37. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence. JAMA 2015;313:1636.
38. D'Onofrio G, Chawarski MC, O'Connor PG, et al. Emergency department-initiated buprenorphine for opioid dependence with continuation in primary care: Outcomes during and after intervention. J Gen Intern Med 2017;32:660-6.
39. Kourounis G, Richards BD, Kyprianou E, et al. Opioid substitution therapy: Lowering the treatment thresholds. Drug Alcohol Depend 2016;161:1-8.
40. Behar E, Santos GM, Wheeler E, et al. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015;148:209-12.